Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Precipio Inc (PRPO) USD0.01

Sell:$2.40 Buy:$3.00 Change: $0.14 (5.43%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Change: $0.14 (5.43%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Change: $0.14 (5.43%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Contact details

12325 Emmet St
United States
+1 (203) 7877888

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$42.03 million
Shares in issue:
17.23 million
Health Care Services
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Douglas Fisher
    Interim Chairman of the Board
  • Ilan Danieli
    President, Chief Executive Officer, Director
  • Carl Iberger
    Chief Financial Officer
  • Ahmed Sabet
    Chief Operating Officer
  • Ori Karev
    Chief Strategy Officer
  • Stephen Miller
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.